Revenue + Forward P/E
UroGen Pharma Ltd. (URGN) quarterly revenue and forward P/EForward P/E: 38.2x
RevenueRevenue (est)Forward P/E
Valuation
Market cap
$2.40B
Enterprise value
$2.40B
P/E ratio (TTM)
-23.72x
P/S ratio (TTM)
12.12x
P/B ratio
-17.87x
EV/Sales
12.74x
EV/EBITDA
-34.01x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$109.79M
Gross profit (TTM)
$97.34M
Operating income (TTM)
$-124.86M
EBITDA (TTM)
$-135.66M
Net income (TTM)
$-153.49M
Free cash flow (TTM)
$-162.73M
Margins & returns
Gross margin
90.85%
Operating margin
-35.32%
Profit margin
-51.73%
Return on equity
81.78%
Return on assets
-38.65%
Per-share metrics
EPS (TTM)
-$1.94
Dividend yield
0.00%
Beta
1.57
Capital structure
Cash & equivalents
$110.75M
Total debt
$128.33M
Net debt
$17.59M
Shares outstanding
48.72M
Financial health
Current ratio
4.01
Debt / equity
-1.22
Debt / assets
0.64
Interest coverage
-3.69
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $629.95B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $443.31B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.09B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.98B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $2.40B | -23.72x | 12.12x | -34.01x | - |